ImmunityBio, Inc.
ImmunityBio, Inc. (IBRX) Revenue
Annual & quarterly revenue history · segment & region breakdown
IBRX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsImmunityBio, Inc. trailing twelve-month (TTM) revenue is $0.14B, an increase of 668.31% year-over-year from $0.11B in FY2025.
Revenue trend
2025 – 2013 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.11B | +$0.10B | +668.31% |
| 2024-12-31 | $0.01B | +$0.01B | +2270.58% |
| 2023-12-31 | $0.00B | +$0.00B | +159.17% |
| 2022-12-31 | $0.00B | -$0.00B | -74.30% |
| 2021-12-31 | $0.00B | +$0.00B | +54.38% |
| 2020-12-31 | $0.00B | +$0.00B | +1306.98% |
| 2019-12-31 | $0.00B | -$0.00B | -8.51% |
| 2018-12-31 | $0.00B | +$0.00B | +4.44% |
| 2017-12-31 | $0.00B | +$0.00B | +2.27% |
| 2016-12-31 | $0.00B | -$0.00B | -81.36% |
Compare revenue vs peers
BiotechnologyCompare IBRX revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income ImmunityBio, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
ImmunityBio, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from ImmunityBio, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IBRX revenue · 4 questionsIBRX's trailing twelve-month (TTM) revenue is $0.14B. That is an increase of 668.31% year-over-year from $0.11B in FY2025.
▸ Source: FMP · ImmunityBio, Inc. SEC filings · GAAP · ImmunityBio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026